Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Coherus BioSciences Inc (NASDAQ:CHRS)

26.78
Delayed Data
As of Sep 30
 +0.49 / +1.86%
Today’s Change
12.04
Today|||52-Week Range
31.98
+16.64%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$1.2B

Company Description

Coherus BioSciences, Inc. engages in the development and commercializition of biosimilar therapeutics worldwide. Its clinical-stage pipeline consists of two anti-inflammatory agents targeting tumor necrosis factor, a substance in the body that is involved in the inflammatory response; and a long-acting form of granulocyte colony-stimulating factor, a beneficial substance in the body that stimulates production of granulocytes (a type of white blood cell) in order to promote the body's ability to fight infections. The company was founded by Dennis M. Lanfear and Stuart E. Builder in September 2010 and is headquartered in Redwood City, CA.

Contact Information

Coherus BioSciences, Inc.
333 Twin Dolphin Drive
Redwood City California 94065
P:(650) 649-3530
Investor Relations:

Employees

Shareholders

Individual stakeholders36.35%
Mutual fund holders34.48%
Other institutional16.85%

Top Executives

Denny M. LanfearChairman, President & Chief Executive Officer
Jean-Frédéric ViretChief Financial Officer
Alan C. HermanChief Scientific Officer
Peter K. WatlerChief Technical Officer
Barbara K. FinckChief Medical Officer